65 results about "B Antibody" patented technology

Disclosed are novel inhibitors of the alternative complement pathway and particularly, novel anti-factor B antibodies. Also disclosed is the use of such inhibitors to reduce or prevent airway hyperresponsiveness and / or airway inflammation by selectively inhibiting the alternative complement pathway, thereby treating diseases in which such conditions play a role. Also disclosed is the use of such inhibitors to reduce or prevent other diseases and conditions, including ischemia-reperfusion injury, by inhibition of the alternative complement pathway.

In certain aspects, the present invention provides compositions and methods for treating fatty liver disease by administering an antagonist of an ActRIIB signaling pathway. Examples of such antagonists include ActRIIB polypeptides, anti-ActRIIB antibodies, anti-myostatin antibodies, anti-GDF3 antibodies and anti-activin A or B antibodies. A variety of hepatic and metabolic disorders may be improved by treating fatty liver disease.

Disclosed is the use of agents and compositions that selectively inhibit the alternative complement pathway for the inhibiting or treating physiological damage resulting from traumatic brain injury (TBI), spinal cord injury (SCI), or related conditions. Preferred reagents for use in inhibition of damage resulting from TBI or SCI include those that inhibit factor B, with anti-factor B antibodies representing a particularly preferred agent.

The present invention provides anti-ED-B antibodies, antibody fragments, and antibody mimetics and such antibodies conjugated to a partner molecule, wherein the antibody or the antibody-partner molecule conjugate provides a therapeutic effect regardless of whether the ED-B-antibody or ED-B-conjugate complex is internalized within a targeted cell.

Disclosed is the use of agents and compositions that selectively inhibit the alternative complement pathway for the inhibiting or treating physiological damage resulting from traumatic brain injury (TBI), spinal cord injury (SCI), or related conditions. Preferred reagents for use in inhibition of damage resulting from TBI or SCI include those that inhibit factor B, with anti-factor B antibodies representing a particularly preferred agent.

This invention relates to humaneered anti-factor B antibodies and antigen-binding fragments thereof with reduced immunogenicity. The humaneered anti-factor B antibodies and antigen-binding fragments thereof are derived from murine monoclonal antibody 1379, which binds factor B in the third short consensus repeat (“SCR”) domain and selectively inhibits activation of the alternative complement pathway by preventing formation of the C3bBb complex. The invention also relates to methods of treating diseases or disorders in which activation of the alternative complement pathway plays a role, and methods of selectively inhibiting activation of the alternative complement pathway in an individual in need thereof.

The invention belongs to the field of biological medicines and discloses an immunochromatography test paper technology, which is used for specifically measuring the negative, positive and titer of IgM, IgG and IgA blood group antibodies in blood or body fluid or tissue fluid or secretion of people. The technology comprises the following steps: (1) preparing a sample filter membrane and a sample pad; (2) preparing a tracer and a tracing pad; (3) preparing a fiber membrane detection area and a quality control area; (4) labeling a test strip; (5) assembling the test strip; (6) injecting a sample and detecting; and (7) reading a result. The test strip can be used for measuring IgM anti-A and anti-B antibody titer, monitoring implantation of bone marrow transplantation and measuring the titer of immune IgG anti-A and anti-B antibodies of individuals, particularly prenatal pregnant women and newborns, the reverse typing of blood groups can be accurately judged by specifically measuring the IgM anti-A and anti-B antibodies, and the reverse typing of the blood group of an individual can be judged through saliva without blood sampling by specifically measuring IgA anti-A and anti-B antibodies in secretion.

The invention relates to the technical field of immunological detection and concretely relates to a kit for magnetic particle chemiluminescent quantitative detection of an anti-SS-B antibody IgG and its preparation method and detection method. The kit for magnetic particle chemiluminescent quantitative detection of an anti-SS-B antibody IgG comprises an Anti-SS-B IgG calibration material, an anti-SS-B IgG regent 1, an anti-SS-B IgG regent 2, an anti-SS-B IgG magnetic separation regent, an anti-SS-B IgG quality control material and a cleaning liquid. The invention also discloses a preparation method and detection method of the kit. Based on the traditional membrane stripe immunization method and enzyme-linked immunosorbent assay, the detection method improves sensitivity and a linear range by 3-5 orders of magnitudes, realizes quantitative determination, has the advantages of high sensitivity, good specificity, good accuracy, low cost, simple operation and objective result determination, realizes full automation by a full-automatic chemiluminescence immunity analyzer and has a wide application prospect.

The invention discloses a protein chip for detecting autoimmune disease markers. A preparation method of the protein chip comprises the following steps: (1) pretreatment of black slide; (2) spotting of antigen solution; (3) blocking technology; preparation of the protein chip. The protein chip of the invention is used for detecting autoimmune disease markers. The joint detection achieved by the use of the company's original protein chip technology can effectively improve detection efficiency and reduce detection costs. The inventor has developed a protein chip diagnostic kit, which simultaneously includes anti-SSA52 antibody, anti-SSA60 antibody, anti-SSB antibody, anti-dsDNA antibody, anti-U1-snRNP antibody, anti-CENP-B antibody, anti-Histone antibody, anti-P0 antibody, anti-Sm antibody,anti-Nucleosome antibody, anti-Scl-70 antibody and anti-Jo-1 antibody. The kit has the advantages of speediness, high efficiency, low cost and the like.

Method for inhibiting tumor cell formation or tumor cell growth, the method comprising administering to a patient in need thereof an antagonist to VEGF-B. Preferably, the antagonist is an anti-VEGF-B antibody, an antisense molecule, an RNAi molecule, a molecule for forming a triplex nucleic acid molecule with a VEGF-B encoding polynucleotide. Also disclosed are pharmaceutical compositions comprising the same.

The present invention relates to an immunoglobulin G concentrate for therapeutic use, in which the respective contents of anti-A and anti-B antibodies are in accordance with a negative result in the in vitro indirect Coombs test. This IgG concentrate also has a polyreactive IgG content of between 0.01% and 0.1%, in particular between 0.07% and 0.1%, relative to the total content of IgG.

Disclosed are novel inhibitors of the alternative complement pathway and particularly, novel anti-factor B antibodies. Also disclosed is the use of such inhibitors to reduce or prevent airway hyperresponsiveness and / or airway inflammation by selectively inhibiting the alternative complement pathway, thereby treating diseases in which such conditions play a role. Also disclosed is the use of such inhibitors to reduce or prevent other diseases and conditions, including ischemia-reperfusion injury, by inhibition of the alternative complement pathway.

The present invention discloses an immune chip for detecting staphylococcal enterotoxin and papaverina dn its preparation process. The immune chip has slide glass with surface treated with silane as aldehydation reagent and crosslinked with glutaraldehyde as double-function crosslinking reagent, and connected via covalent bond with the molecule of at least one kind of antibody staphylococcal enteriotoxin A antibody, staphylococcal enterotoxin B antibody, staphylococcal enterotoxin C antibody and papaverine antibody. The detection with the immune chip is simple, effective and low in cost.

The invention discloses a high-flux ultra-sensitive double-labeled time-resolved immunochromatographic test strip and application thereof. The high-flux ultra-sensitive double-label time-resolved immunochromatographic test strip comprises a sample pad, a nitrocellulose film, a water absorption pad and a PVC bottom plate, wherein two detection lines and a quality control line are arranged on the nitrocellulose film; the detection line is respectively coated with antigens of a small molecular compound A and a small molecular compound B; and the quality control line is coated with a goat anti-chicken antibody. The invention also discloses a complete set of time-resolved fluorescent microsphere coupled antibody probe, which consists of a time-resolved fluorescent microsphere labeled anti-smallmolecule compound A antibody, a time-resolved fluorescent microsphere labeled anti-small molecule compound B antibody and a time-resolved fluorescent microsphere labeled chicken IgY antibody. The test strip and the complete set of time-resolved fluorescent microsphere coupled antibody probe can be used for rapidly, sensitively and accurately detecting various small molecular harmful compounds.

It is described a Clostridium difficile (C-difficile) toxins A and / or B as a target for therapy, including passive immunotherapy, and particularly prevention of C-difficile intoxication in human or other animals. It is also described a polypeptide comprising a portion of C-difficile toxins A and / or B sequence being an epitope for anti-toxins A and / or B antibody. It disclosed a method for generating a neutralizing antibody directed against C-difficile toxins A and / or B. It is also provided a novel formulation that combines key toxins A and / or B epitope antibodies, located in three key domains of toxins A and / or B, for neutralisation of the toxins A and / or B, at any stage of toxins A and / or B intoxication related to C-difficile infection. The novel formulation of toxins A and / or B epitope antibodies are useful in immunotherapy, for 10 therapeutic and / or prophylactic mediation of C-difficile intoxication.

The invention discloses a detection test paper. The test paper comprises (1) a reaction support, (2) a water absorption pad, (3) a nitrocellulose membrane, (4) a gold-labeled antibody adsorption membrane and (5) a sample pad, wherein the nitrocellulose membrane is coated with a detection strip and a quality control strip of a staphylococcal enterotoxin B antibody and a quality control antibody; and the gold-labeled antibody adsorption membrane contains the staphylococcal enterotoxin B antibody labeled by colloidal gold. The test paper can be matched with a small instrument to carry out semi-quantitative detection, does not need professional training, has clear and identifiable result, can objectively store data, is simple to operate, easy to popularize, suitable for a basic level, suitable for field detection of emergency and suitable for epidemiological investigation, and plays an auxiliary role in diagnosis of staphylococcal enterotoxin B infection.

The invention belongs to the technical field of biology, and discloses a kit for classificatory detection of helicobacter pylori. The kit comprises a blotting membrane transferred with whole helicobacter pylori protein subjected to electrophoretic separation. The kit is used for detecting multiple Hp antibodies such as pathogenic factor cytotoxin (CagA), vacuolating cytotoxin (VacA) and urease subunit A and B antibodies in the serum of a helicobacter pylori infected person by adopting immuno-blotting, determining whether the infected Hp produces strains or not according to different Hp antibodies and further judging the serological types of the Hp strains infecting patients. The kit only requires an examinee to provide the serum, belongs to noninvasive examination, and is high in compliance of the patients, quick in detection (the whole time is only 2 hours), low in demand of samples (only 10 milliliters of examined serum is required), high in specificity, high in sensitivity, wide in application range and convenient to popularize and use in hospitals and hygiene departments.

The invention concerns the prevention and treatment of complement-associated eye conditions, such as choroidal neovascularization (CNV) and age-related macular degeneration (AMD), by administration of factor B antagonists.

The invention discloses a CD 3 and PRLR duplex-specific antibody and construction and application thereof. A construction method of the CD 3 and PRLR duplex-specific antibody comprises the steps thatheavy and light chain plasmids pM-CD3Hc, pM-CD3Lc and pM-IntCRc of a target CD 3 antibody fusion protein IntC are constructed, subjected to transient cotransfection to be transferred into a cell and subjected to affinity purification, and thus a fragment A antibody is obtained; heavy and light chain plasmids pM-PRLRIntN and pM-PRLRLc of a target PRLR antibody fusion protein IntN are constructed, subjected to transient cotransfection to be transferred into the cell and subjected to affinity purification, and thus a fragment B antibody is obtained; the fragment A antibody and the fragment B antibody are subjected to external trans-splicing, and thus the CD 3 and PRLR duplex-specific antibody is obtained. The CD 3 and PRLR duplex-specific antibody provides a new target therapy strategy for current breast cancer HER 2 and ER target treatment; compared with a PRLR blocking antibody, the PRLR-DbsAb has a more obvious inhibiting effect on tumours.

The invention provides an improvement method of quick test paper of helicobacter pylori. The method comprises the following steps: orderly connecting a sample absorbing pad, a nitrocellulose membrane,and a water-absorbing layer from left to right, and fixing on a bottom plate, wherein a first detection line, a second detection line and a control line C which are mutually separated are coated on the nitrocellulose membrane, the first detection line is the colloidal gold marked rat-anti urease antibody, the second detection line is the colloidal gold marked rat-anti heat shock protein B antibody, and the control line C is the colloidal gold marked goat-anti-rat polyclonal antibody; wrapping the bottom plate, the sample absorbing pad, the nitrocellulose membrane and the water absorbing layerby using a plastic shell, and forming a sample injection hole on the plastic shell; dropping the saliva on the sample absorbing pad through the sample injection hole; preparing the sealed 5ml treating bottle and 3ml suckers, wherein 2ml of treating liquid is held in the treating bottle, and the treating liquid contains 30mg / L of ambroxol hydrochloride, 10g / L of phosphate-tween 20 buffer solutionof sodium bicarbonate.

The invention relates to novel bispecific antibodies and their use in tumor therapy. The novel antibodies have the ability to bind to ErbB receptors, preferably ErbB1 receptors, which are overexpressed on many cancer tissues. Since the different specificities of the antigen-binding sites are directed to different epitopes within the binding domain of same or different ErbB receptors, these antibodies are more effective with respect to inhibition and down-regulation of the ErbB receptor and the corresponding signaling cascade.

In certain aspects, the present invention provides compositions and methods for treating fatty liver disease by administering an antagonist of an ActRIIB signaling pathway. Examples of such antagonists include ActRIIB polypeptides, anti-ActRIIB antibodies, anti-myostatin antibodies, anti-GDF3 antibodies and anti-activin A or B antibodies. A variety of hepatic and metabolic disorders may be improved by treating fatty liver disease.

The invention relates to a human ABO blood type reverse typing colloidal gold test strip as well as a preparation method and application thereof. The human ABO blood type reverse typing colloidal gold test strip is composed of a base plate, a sample pad, a colloidal gold pad, a nitrocellulose membrane and absorbent paper. When a to-be-detected sample is dripped into a sample adding area, specific binding occurs between type A and B antibodies in the samples and colloidal gold labeled antigens A and B on the test strip, the compound moves forwards along the nitrocellulose membrane under the siphon action and is captured by antibodies in a detection area when being moved into the detection area, an antibody-antigen-antibody-colloidal gold double-antibody sandwich compound is formed and accumulated on a detection line to present a visible developing reaction. If the to-be-detected antibody does not exist in the sample, binding does not occur, that is, developing is avoided. The test strip disclosed by the invention has the advantages of being high in sensitivity, convenient to use, objective in results, low in cost, convenient to preserve and transport, and the like.

The invention relates to a kit applied to detecting apoA I and apo B and a preparation method of a stabilizer of the kit. The kit comprises apo A antibody liquid, apo B antibody liquid and liquid serotype constant value calibration solution, and also comprises the stabilizer; the stabilizer comprises the following components in parts by weight: 1-5 parts of trehalose, 100-200 parts of 0.01mol / L phosphate buffer, 1-5 parts of horseradish peroxidase, 0.01-0.1 part of sodium propionate and 1-5 parts of thiomersalate. By using the stabilizer, the stability of the antibodies is enhanced, and thus the preservation life and the service life are prolonged, the stability of the kit when in use is enhanced, and the trehalose can protect the stability of biomacromolecule structure and functions whenliving bodies are coerced by bad environment conditions.

The invention discloses a high-flux ultra-sensitive fluorescent gold nano-cluster immunochromatographic test strip and application thereof. The fluorescent gold nano-cluster immunochromatography teststrip comprises a sample pad, a nitrocellulose membrane, absorbent paper and a PVC viscous bottom plate; the nitrocellulose membrane is coated with two target object detection lines and a quality control line. The invention also discloses a complete set of fluorescent gold nano-cluster coupling antibody probe, which is composed of a streptavidin fluorescent gold nano-cluster labeled biotinylated anti-small molecule compound A antibody and a streptavidin fluorescent gold nano-cluster labeled biotinylated anti-small molecule compound B antibody. The fluorescent gold nano-cluster is a green fluorescent gold nano-cluster which takes 6-aza-2-thiopyrimidine and arginine as ligands and has super-strong fluorescence. The test strip has the advantages that the method is simple and rapid, the resultis visual and accurate, quantitative / semi-quantitative detection can be achieved, and high-flux ultra-sensitive online detection of veterinary drug residues can be achieved.

The present invention relates to antibodies with sub-nanomolar affinity specific for a characteristic epitope of the ED-B domain of fibronectin, a marker of angiogenesis. Furthermore, it relates to the use of radiolabelled high affinity anti ED-B antibodies for detecting new-forming blood vessels in vivo and a diagnostic kit comprising comprising said antibody. Furthermore, it relates to conjugates comprising said antibodies and a suitable photoactive molecules (e.g. an appropriately chosen photosensitizer or radionuclide), and their use for the selective light-mediated occlusion of new blood vessels.

Induction of an anergic response by NF-ºB inhibitors and the inhibition of immune response by the administration of an inhibitor of NF-ºB is disclosed. Examples ofNF-ºB inhibitors include IºB±, PSI, a nucleotide encoding IºB± anti-sense nucleic acid encoding an NF-ºB sequence, such as RelB, and anti- NF-ºB antibodies. Also disclosed are vectors encoding inducers and inhibitors of NF-ºB, for example adenoviral vectors.

The invention discloses an anti-SS-B antibody IgG chemiluminescent immunoassay kit, which comprises SS-B antigen coated magnetic particles, mouse-anti-human IgG monoclonal antibody coated acridinium ester, an anti-SS-B antibody IgG calibrated product, a pre-activating liquid, and an activating liquid. The invention further discloses a preparation method of the anti-SS-B antibody IgG chemiluminescent immunoassay kit. Compared with the conventional kits, the provided kit has the advantages of simple operation, high sensitivity, and wide detection range.